Algisyl-LVR在慢性心力衰竭中的研究进展

王辉波; 杨俊

doi:10.13201/j.issn.1001-1439.2015.08.002

Algisyl-LVR在慢性心力衰竭中的研究进展

王辉波,
杨俊^,

- 三峡大学心血管病研究所三峡大学第一临床医学院心内科 (湖北宜昌, 443003)
基金项目:
国家自然科学基金（No：81170133，81200088，81470387）；宜昌市科技研究与开发项目（No：A12301-01）；三峡大学研究生科研创新基金（2015CX098）；湖北省首届医学领军人才基金

详细信息

通讯作者: 杨俊,E-mail:yangjun@medmail.com.cn

中图分类号: R541.6

收稿日期: 2014-12-29

修回日期: 2015-03-12

Research of Algisyl-LVR in chronic heart failure

WANG Huibo,
YANG Jun^,

- Department of Cardiology, The First College of Clinical Medical Science, China Three Gorges University, Yichang Central People's Hospital, Yichang, Hubei, 443003, China

More Information

Corresponding author: YANG Jun, E-mail: yangjun@medmail.com.cn

Received Date: 29 December 2014

Revised Date: 12 March 2015

摘要

摘要: 慢性心力衰竭（chronic heart failure，CHF）是大多数心血管疾病的最终归宿，因具有高发病率、高病死率而引起人们的关注。CHF的标志是左心室进行性扩张、左室壁压力的增加，导致心肌耗氧量增加。根据拉普拉斯定律，运用一种组织工程学技术增加室壁厚度、减少心室腔直径，从而减少室壁压力、改善左室功能，本文总结归纳了这种组织工程技术在治疗CHF中的作用机制和Algisyl-LVR相关的试验结果。
- Algisyl-LVR /
- 慢性心力衰竭 /
- 作用机制
Abstract: Chronic heart failure (CHF) is the end result of various cardiovascular diseases.It has caused much concern because of its high morbidity and mortality. The hallmark of CHF is the progressive dilatation of the left ventricle, thinning of the left ventricular wall leading to increased wall stress and increased myocardial oxygen consumption. Applying Laplace's law, utilizes a tissue engineering strategy to increase wall thickness and reduce chamber volume, resulting in a decrease in wall stress and improved left ventricular function. The present review primarily focuses on the rationale for an tissue engineering approach for this treatment of CHF and experiment results of the Algisyl-LVR program are presented treatment of heart failure.
- Algisyl-LVR /
- chronic heart failure /
- mechanism

HTML全文

参考文献(18)

[1]	GASIOROWSKI A, DUTKIEWICZ J. Comprehensive rehabilitation in chronic heart failure[J]. Ann Agric Environ Med, 2013, 20:606-612.
[2]	GUO Y, LIP G Y H, BANERJEE A. Heart failure in East Asia[J]. Curr Cardiol Rev, 2013, 9:112-122.
[3]	GRODIN J L, TANG W H. Treatment strategies for the prevention of heart failure[J]. Curr Heart Fail Rep, 2013, 10:331-340.
[4]	GARBADE J, BARTEN M J, BITTNER H B, et al. Heart transplantation and left ventricular assist device therapy:two comparable options in end-stage heart failure?[J]. Clin Cardiol, 2013, 36:378-382.
[5]	ADAMOPOULOS S, GOUZIOUTA A, MANTZOURATOU P, et al. Thyroid hormone signalling is altered in response to physical training in patients with end-stage heart failure and mechanical assist devices:potential physiological consequences?[J]. Interact Cardiovasc Thorac Surg, 2013:17:664-668.
[6]	SMIT F E, DOHMEN P M. Bio-artificial heart as ultimate treatment of end-stage heart failure[J]. Med Sci Monit Basic Res, 2014, 20:161-163.
[7]	GLICK D, DEFILIPPI C R, CHRISTENSON R, et al. Long-term trajectory of two unique cardiac biomarkers and subsequent left ventricular structural pathology and risk of incident heart failure in community-dwelling older adults at low baseline risk[J]. JACC:Heart Fail, 2013, 1:353-360.
[8]	LEE R J, HINSON A, HELGERSON S, et al. Polymer-based restoration of left ventricular mechanics[J]. Cell Transplant, 2013, 22:529-533.
[9]	LEE L C, ZHIHONG Z, HINSON A, et al. Reduction in left ventricular wall stress and improvement in function in failing hearts using Algisyl-LVR[J]. J Vis Exp, 2013, 8:e50096.
[10]	王海滨. 基于可注射性水凝胶支架材料的心肌组织工程研究[D]. 中国人民解放军军事医学科学院, 2010.
[11]	LEE L C, WALL S T, KLEPACH D, et al. Algisyl-LVR^TM with coronary artery bypass grafting reduces left ventricular wall stress and improves function in the failing human heart[J]. Int J Cardiol, 2013, 168:2022-2028.
[12]	SABBAH H N, WANG M, JIANG A, et al. Circumferential mid-ventricular intramyocardial injections of alginate hydrogel improve left ventricular function and prevent progressive remodeling in dogs with chronic heart failure[J]. Circulation, 2009, 120:S912-S912.
[13]	SABBAH H N, WANG M, GUPTA R C, et al. Augmentation of left ventricular wall thickness with alginate hydrogel implants improves left ventricular function and prevents progressive remodeling in dogs with chronic heart failure[J]. JACC Heart Fail, 2013, 1:252-258.
[14]	RAMANI G V, UBER P A, MEHRA M R. Chronic heart failure:contemporary diagnosis and management[C].Mayo Clin Proc, 2010, 85:180-195.
[15]	SOLOMON S D, ZILE M, PIESKE B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction:a phase 2 double-blind randomised controlled trial[J]. The Lancet, 2012, 380:1387-1395.
[16]	MURRAY J J V, PACKER M, DESAI A S, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure:rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)[J]. Eur J Heart Fail, 2013, 15:1062-1073.
[17]	SÁNCHEZ L A, GUERRERO-BELTRÁN C E, CORDERO-REYES A M, et al. Use of stem cells in heart failure treatment:where we stand and where we are going[J]. Methodist DeBakey Cardiovasc J, 2013, 9:195-200.
[18]	KISHIMOTO I, TOKUDOME T, HOSODA H, et al. Ghrelin and cardiovascular diseases[J]. J Cardiol, 2012, 59:8-13.